lp-300
Generic: Sodium 2,2'-disulfanediyldiethanesulfonate
lp-300: sourced relationships with 1 company · 1 clinical trial tracked.
lp-300 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect lp-300 to LTRN; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could lp-300 → LTRN affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Adenocarcinoma of Lung
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Lantern Pharma Inc. (LTRN) Adenocarcinoma of Lung | Phase 2 |
Clinical Trial Registry Records (1)
Phase II Trial of LP-300 in Combination With Carboplatin and Pemetrexed in Never Smoker Patients With Relapsed Advanced Primary Adenocarcinoma of the Lung After Treatment With Tyrosine Kinase Inhibitors (The HARMONIC Study)
Primary endpoint: Progression-free survival (PFS)
InterventionalRandomizedopen90 targetStarted 2023-03Completion 2027-0616 sites · Japan, Taiwan, United StatesLantern Pharma Inc.
Frequently asked questions
Which companies have sourced relationships with lp-300?
lp-300 has dated SEC/FDA relationship records for Lantern Pharma Inc..
How many clinical trials involve lp-300?
BioSniper tracks 1 clinical trial involving lp-300.